Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H1N1 influenza antigen
- Development stage
- Unknown
- Lead developer
- Vaxess Technologies
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Transdermal
01
Overview
H1N1 influenza antigen is a component of influenza vaccines designed to elicit an immune response against the H1N1 strain of the influenza virus. It was supplied by GC Biopharma for use by Vaxess Technologies in their VX-103 MIMIX-Flu patch program, which aims to improve flu vaccine efficacy and durability compared to traditional injections. A Phase 1 trial for this program, which utilized the H1N1 influenza antigen, was completed in June 2023 and demonstrated strong and durable immune responses.
- Other names
- H1N1 influenza antigenH-1N1 influenza antigenH 1N1 influenza antigen
Beyond the preview
Go deeper on H1N1 influenza antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H1N1 influenza antigen.